Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GH therapy in Noonan syndrome: Review of final height data.

Hormone research - 1 Dec 2009

Dahlgren Jovanna

Abstract excerpt

BACKGROUND AND AIMS: Several studies, despite using small cohorts, have shown a short-term improvement in the height velocity of short children with Noonan syndrome (NS) when treated with recombinant growth hormone (GH). However, the question is whether or not this improvement is sustained until adult height is reached. This paper reviews the few studies reporting final height data of GH treatment in individuals...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Body Height
Share to Growth

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Human Growth Hormone

Share to Noonan Syndrome

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Puberty

Share to Sex Factors

Source

Identifiers

PMID: 20029237
DOI: 10.1159/000243779

Genes

PTPN11
SDS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GH therapy in Noonan syndrome: Review of final height data.PMID 20029237Read ↗

Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.Semantic proximity Read ↗

Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.Semantic proximity Read ↗

Efficacy and safety of growth hormone therapy in children with Noonan syndrome.Semantic proximity Read ↗

Growth hormone therapy in Noonan syndrome: growth response and characteristics.Semantic proximity Read ↗

Abnormal growth in noonan syndrome: the challenge of optimal therapy.Semantic proximity Read ↗

Expanding the genetic spectrum of Noonan syndrome.Semantic proximity Read ↗

Short stature and its treatment in Turner and Noonan syndromes.Semantic proximity Read ↗

Noonan syndrome spectrum disorders in real life: patient characteristics and response to growth hormone therapy in a genetically defined single-country multicenter cohort.Semantic proximity Read ↗

[Noonan syndrome: from phenotype to growth hormone therapy].Semantic proximity Read ↗

Noonan syndrome: relationships between genotype, growth, and growth factors.Semantic proximity Read ↗

PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.Semantic proximity Read ↗

GH Therapy and first final height data in Noonan-like syndrome with loose anagen hair (Mazzanti syndrome).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.